{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T08:03:36Z","timestamp":1777277016193,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["11289"],"award-info":[{"award-number":["11289"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017636","name":"Cancer Center Amsterdam","doi-asserted-by":"publisher","award":["2021-2-29"],"award-info":[{"award-number":["2021-2-29"]}],"id":[{"id":"10.13039\/501100017636","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Radiolabelled fibroblast activation protein inhibitors (FAPI) are promising molecular imaging tracers for the diagnosis and staging of pancreatobiliary cancer. To enable treatment response assessment with [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46, the day-to-day variability of its uptake must be defined. This study aimed to determine the repeatability of semi-quantitative [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46 PET\/CT measurements in pancreatobiliary cancers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with pathologically confirmed pancreatobiliary cancer (pancreatic ductal adenocarcinoma (PDAC) or cholangiocarcinoma (CCA)) were included. Patients underwent two [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46 PET\/CT scans, within 7 days, without any treatment before or between scans. Static long axial field-of-view (LAFOV) PET\/CT scans were performed 60\u00a0min post-injection of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46 (EARL2-compliant reconstruction). Suspected malignant lesions were semi-automatically delineated (local background-adjusted 50% isocontour of the peak standardised uptake value (SUV)) and semi-quantitative measurements were extracted (SUV\n                      <jats:sub>mean<\/jats:sub>\n                      , SUV\n                      <jats:sub>peak<\/jats:sub>\n                      and SUV\n                      <jats:sub>max<\/jats:sub>\n                      ). Tumour-to-background ratios (TBR) were also calculated. Repeatability was assessed using the repeatability coefficient (RC) and the intraclass correlation coefficient (ICC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twelve patients were included (seven PDAC, three perihilar CCA and two intrahepatic CCA). The median injected dose was 216 MBq (interquartile range (IQR) 167\u2013266 MBq) and the median uptake time was 60\u00a0min (range 60\u201368). In total, 70 FAPI-positive lesions were delineated. The RCs of SUV\n                      <jats:sub>mean<\/jats:sub>\n                      , SUV\n                      <jats:sub>peak<\/jats:sub>\n                      and SUV\n                      <jats:sub>max<\/jats:sub>\n                      were 23.7%, 23.9% and 29.8%, respectively. For the blood pool adjusted TBR\n                      <jats:sub>mean<\/jats:sub>\n                      , TBR\n                      <jats:sub>peak<\/jats:sub>\n                      and TBR\n                      <jats:sub>max<\/jats:sub>\n                      , the RC\u2019s were 21.6%, 20.8% and 28.0%, respectively. All ICCs were above 0.98.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Semi-quantitative measurements of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-FAPI-46 PET\/CT have an excellent repeatability and can potentially be used in future studies to assess treatment response in pancreatobiliary cancers.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07738-6","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:55:26Z","timestamp":1768524926000},"page":"3827-3837","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Repeatability of semi-quantitative [68Ga]Ga-FAPI-46 PET\/CT measurements in pancreatobiliary cancers: a test-retest study"],"prefix":"10.1007","volume":"53","author":[{"given":"Rutger B.","family":"Henrar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthijs C. F.","family":"Cysouw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Palard-Novello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lothar A.","family":"Schwarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter G. H. M.","family":"Raijmakers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lioe-Fee","family":"de Geus-Oei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander L.","family":"Vahrmeijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert","family":"Kazemier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert D.","family":"Windhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Boellaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maqsood","family":"Yaqub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3980-4634","authenticated-orcid":false,"given":"Rutger-Jan","family":"Swijnenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"7738_CR1","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415\u201322. https:\/\/doi.org\/10.2967\/jnumed.118.210443.","journal-title":"J Nucl Med"},{"key":"7738_CR2","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","volume":"60","author":"A Loktev","year":"2019","unstructured":"Loktev A, Lindner T, Burger EM, Altmann A, Giesel F, Kratochwil C, et al. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. J Nucl Med. 2019;60:1421\u20139. https:\/\/doi.org\/10.2967\/jnumed.118.224469.","journal-title":"J Nucl Med"},{"key":"7738_CR3","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.2967\/jnumed.122.264827","volume":"64","author":"L Kessler","year":"2023","unstructured":"Kessler L, Hirmas N, Pabst KM, Hamacher R, Ferdinandus J, Schaarschmidt BM, et al. (68)Ga-labeled fibroblast activation protein inhibitor ((68)Ga-FAPI) PET for pancreatic adenocarcinoma: data from the (68)Ga-FAPI PET observational trial. J Nucl Med. 2023;64:1910\u20137. https:\/\/doi.org\/10.2967\/jnumed.122.264827.","journal-title":"J Nucl Med"},{"key":"7738_CR4","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2967\/jnumed.122.265215","volume":"64","author":"KM Pabst","year":"2023","unstructured":"Pabst KM, Trajkovic-Arsic M, Cheung PFY, Ballke S, Steiger K, Bartel T, et al. Superior tumor detection for (68)Ga-FAPI-46 versus (18)F-FDG PET\/CT and conventional CT in patients with cholangiocarcinoma. J Nucl Med. 2023;64:1049\u201355. https:\/\/doi.org\/10.2967\/jnumed.122.265215.","journal-title":"J Nucl Med"},{"key":"7738_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26051978","author":"RB Henrar","year":"2025","unstructured":"Henrar RB, Vuijk FA, Burchell GL, van Dieren S, de Geus-Oei LF, Kazemier G, et al. Diagnostic performance of radiolabelled FAPI versus [(18)F]FDG PET imaging in hepato-pancreato-biliary oncology: a systematic review and meta-analysis. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26051978.","journal-title":"Int J Mol Sci"},{"key":"7738_CR6","unstructured":"Institute NC. SEER*Explorer: an interactive website for SEER cancer statistics. National Cancer Institute; 2023."},{"key":"7738_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/gutjnl-2017-314828","volume":"68","author":"L Huang","year":"2019","unstructured":"Huang L, Jansen L, Balavarca Y, Molina-Montes E, Babaei M, van der Geest L, et al. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut. 2019;68:130\u20139. https:\/\/doi.org\/10.1136\/gutjnl-2017-314828.","journal-title":"Gut"},{"key":"7738_CR8","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s00261-024-04267-y","volume":"49","author":"J Cao","year":"2024","unstructured":"Cao J, Srinivas-Rao S, Mroueh N, Anand R, Kongboonvijit S, Sertic M, et al. Cholangiocarcinoma imaging: from diagnosis to response assessment. Abdom Radiol. 2024;49:1699\u2013715. https:\/\/doi.org\/10.1007\/s00261-024-04267-y.","journal-title":"Abdom Radiol"},{"key":"7738_CR9","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jama.2024.16332","volume":"332","author":"G Perrotta","year":"2024","unstructured":"Perrotta G, Mohamed G, Larson BK, Osipov A, Ferrone CR, Lo SK, et al. Accuracy of clinical staging in early-stage pancreatic ductal adenocarcinoma. JAMA. 2024;332:1108\u201310. https:\/\/doi.org\/10.1001\/jama.2024.16332.","journal-title":"JAMA"},{"key":"7738_CR10","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.21037\/jgo-22-1034","volume":"14","author":"M Fiore","year":"2023","unstructured":"Fiore M, Coppola A, Petrianni GM, Trecca P, D\u2019Ercole G, Cimini P, et al. Advances in pre-treatment evaluation of pancreatic ductal adenocarcinoma: a narrative review. J Gastrointest Oncol. 2023;14:1114\u201330. https:\/\/doi.org\/10.21037\/jgo-22-1034.","journal-title":"J Gastrointest Oncol"},{"key":"7738_CR11","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395\u2013406. https:\/\/doi.org\/10.1056\/NEJMoa1809775.","journal-title":"N Engl J Med"},{"key":"7738_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-6610-4","volume":"20","author":"TO Goetze","year":"2020","unstructured":"Goetze TO, Bechstein WO, Bankstahl US, Keck T, Konigsrainer A, Lang SA, et al. Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC\/ECC) - a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO\/ CALGP\/ ACO- GAIN-trial. BMC Cancer. 2020;20:122. https:\/\/doi.org\/10.1186\/s12885-020-6610-4.","journal-title":"BMC Cancer"},{"key":"7738_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.109358","volume":"51","author":"B Ten Haaft","year":"2025","unstructured":"Ten Haaft B, Sickmann MMT, Nooijen LE, Ali M, Wilmink JW, Klumpen HJ, et al. Gemcitabine-cisplatin induction treatment in patients with locally advanced perihilar cholangiocarcinoma (IMPACCA): a prospective registration study. Eur J Surg Oncol. 2025;51:109358. https:\/\/doi.org\/10.1016\/j.ejso.2024.109358.","journal-title":"Eur J Surg Oncol"},{"key":"7738_CR14","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","volume":"40","author":"E Versteijne","year":"2022","unstructured":"Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022;40:1220\u201330. https:\/\/doi.org\/10.1200\/JCO.21.02233.","journal-title":"J Clin Oncol"},{"key":"7738_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41575-023-00856-2","volume":"21","author":"TF Stoop","year":"2024","unstructured":"Stoop TF, Theijse RT, Seelen LWF, Groot Koerkamp B, van Eijck CHJ, Wolfgang CL, et al. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024;21:101\u201324. https:\/\/doi.org\/10.1038\/s41575-023-00856-2.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7738_CR16","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.6004\/jnccn.2022.7041","volume":"20","author":"AM Abdelrahman","year":"2022","unstructured":"Abdelrahman AM, Goenka AH, Alva-Ruiz R, Yonkus JA, Leiting JL, Graham RP, et al. FDG-PET predicts neoadjuvant therapy response and survival in borderline Resectable\/Locally advanced pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2022;20:1023\u2013e323. https:\/\/doi.org\/10.6004\/jnccn.2022.7041.","journal-title":"J Natl Compr Canc Netw"},{"key":"7738_CR17","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.7150\/thno.95329","volume":"14","author":"G Metzger","year":"2024","unstructured":"Metzger G, Bayerl C, Rogasch JM, Furth C, Wetz C, Beck M. 68 Ga-labeled fibroblast activation protein inhibitor (FAPI) PET\/CT for locally advanced or recurrent pancreatic cancer staging and restaging after chemoradiotherapy. Theranostics. 2024;14:4184\u201397. https:\/\/doi.org\/10.7150\/thno.95329.","journal-title":"Theranostics"},{"key":"7738_CR18","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1007\/s00259-023-06271-8","volume":"50","author":"Z Zhu","year":"2023","unstructured":"Zhu Z, Cheng K, Yun Z, Zhang X, Hu X, Liu J. [18F] AlF-NOTA-FAPI-04 PET\/CT can predict treatment response and survival in patients receiving chemotherapy for inoperable pancreatic ductal adenocarcinoma. Eur J Nucl Med Mol Imaging. 2023;50:3425\u201338. https:\/\/doi.org\/10.1007\/s00259-023-06271-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7738_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07271-6","author":"X Li","year":"2025","unstructured":"Li X, Lu N, Sun K, Shi F, Lin L, Chen Y, et al. [(18)F]FAPI- 04 PET\/CT for pathologic response assessment in pancreatic cancer patients with systemic treatment. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07271-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7738_CR20","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1007\/s00259-024-07037-6","volume":"52","author":"X Palard-Novello","year":"2025","unstructured":"Palard-Novello X, Henrar RB, Oprea-Lager DE, Cysouw MCF, Schober P, de Geus-Oei LF, et al. Assessment of fully quantitative and simplified methods for analysis of [(68)Ga]Ga-FAPI-46 uptake in patients with pancreatobiliary cancer using LAFOV PET\/CT. Eur J Nucl Med Mol Imaging. 2025;52:1472\u201380. https:\/\/doi.org\/10.1007\/s00259-024-07037-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7738_CR21","unstructured":"Boellaard R. Quantitative oncology molecular analysis suite: ACCURATE [abstract]. J Nucl Med. 2018;59(suppl 1):1753."},{"key":"7738_CR22","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.2967\/jnumed.119.236075","volume":"61","author":"BHE Jansen","year":"2020","unstructured":"Jansen BHE, Cysouw MCF, Vis AN, van Moorselaar RJA, Voortman J, Bodar YJL, et al. Repeatability of quantitative (18)F-DCFPyL PET\/CT measurements in metastatic prostate cancer. J Nucl Med. 2020;61:1320\u20135. https:\/\/doi.org\/10.2967\/jnumed.119.236075.","journal-title":"J Nucl Med"},{"key":"7738_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-024-00628-0","volume":"11","author":"X Palard-Novello","year":"2024","unstructured":"Palard-Novello X, Visser D, Tolboom N, Smith CLC, Zwezerijnen G, van de Giessen E, et al. Validation of image-derived input function using a long axial field of view PET\/CT scanner for two different tracers. EJNMMI Phys. 2024;11:25. https:\/\/doi.org\/10.1186\/s40658-024-00628-0.","journal-title":"EJNMMI Phys"},{"key":"7738_CR24","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1148\/radiol.2016142043","volume":"280","author":"JH O","year":"2016","unstructured":"O JH, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280:576\u201384. https:\/\/doi.org\/10.1148\/radiol.2016142043.","journal-title":"Radiology"},{"key":"7738_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/biomet\/31.1-2.9","volume":"31","author":"EJG Pitman","year":"1939","unstructured":"Pitman EJG. A note on normal correlation*. Biometrika. 1939;31:9\u201312. https:\/\/doi.org\/10.1093\/biomet\/31.1-2.9.","journal-title":"Biometrika"},{"key":"7738_CR26","first-page":"65","volume":"6","author":"S Holm","year":"1979","unstructured":"Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65\u201370.","journal-title":"Scand J Stat"},{"key":"7738_CR27","first-page":"278","volume-title":"Contributions to probability and statistics: essays in honor of Harold hotelling","author":"H Levene","year":"1960","unstructured":"Levene H. Robust tests for equality of variances. In: Olkin I, editor. Contributions to probability and statistics: essays in honor of Harold hotelling. Palo Alto, CA: Stanford University Press; 1960. pp. 278\u201392."},{"key":"7738_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.62347\/DCGC3250","volume":"15","author":"H Meng","year":"2025","unstructured":"Meng H, Pan G, Peng Y, Yang J, Cui B, Zhang Y, et al. The reproducibility of [68Ga]Ga-FAPI-04 PET uptake parameters at 15 min and 60 min post-injection. Am J Nucl Med Mol Imaging. 2025;15:74\u201381. https:\/\/doi.org\/10.62347\/DCGC3250.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"7738_CR29","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2967\/jnumed.111.095299","volume":"53","author":"AJ de Langen","year":"2012","unstructured":"de Langen AJ, Vincent A, Velasquez LM, van Tinteren H, Boellaard R, Shankar LK, et al. Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis. J Nucl Med. 2012;53:701\u20138. https:\/\/doi.org\/10.2967\/jnumed.111.095299.","journal-title":"J Nucl Med"},{"key":"7738_CR30","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2967\/jnumed.116.186353","volume":"58","author":"MA Lodge","year":"2017","unstructured":"Lodge MA. Repeatability of SUV in oncologic (18)F-FDG PET. J Nucl Med. 2017;58:523\u201332. https:\/\/doi.org\/10.2967\/jnumed.116.186353.","journal-title":"J Nucl Med"},{"key":"7738_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","volume":"261","author":"CR Ferrone","year":"2015","unstructured":"Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261:12\u20137. https:\/\/doi.org\/10.1097\/SLA.0000000000000867.","journal-title":"Ann Surg"},{"key":"7738_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znae033","author":"RT Theijse","year":"2024","unstructured":"Theijse RT, Stoop TF, Janssen QP, Prakash LR, Katz MHG, Doppenberg D, et al. Impact of a non-therapeutic laparotomy in patients with locally advanced pancreatic cancer treated with induction (m)FOLFIRINOX: trans-Atlantic Pancreatic Surgery (TAPS) Consortium study. Br J Surg. 2024. https:\/\/doi.org\/10.1093\/bjs\/znae033.","journal-title":"Br J Surg"},{"key":"7738_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164155","author":"M Ghidini","year":"2021","unstructured":"Ghidini M, Vuozzo M, Galassi B, Mapelli P, Ceccarossi V, Caccamo L, et al. The role of positron emission tomography\/computed tomography (PET\/CT) for staging and disease response assessment in localized and locally advanced pancreatic cancer. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13164155.","journal-title":"Cancers (Basel)"},{"key":"7738_CR34","doi-asserted-by":"publisher","first-page":"93S","DOI":"10.2967\/jnumed.110.085662","volume":"2","author":"R Boellaard","year":"2011","unstructured":"Boellaard R. Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis. J Nucl Med. 2011;2:93S-100S. https:\/\/doi.org\/10.2967\/jnumed.110.085662.","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"7738_CR35","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):S122\u201350. https:\/\/doi.org\/10.2967\/jnumed.108.057307.","journal-title":"J Nucl Med"},{"issue":"1","key":"7738_CR36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1158\/1078-0432.CCR-21-3143","volume":"29","author":"LK Shankar","year":"2023","unstructured":"Shankar LK, Huang E, Litiere S, Hoekstra OS, Schwartz L, Collette S, et al. <article-title update=\"added\">Meta-analysis of the test\u2013retest repeatability of [18F]-fluorodeoxyglucose standardized uptake values: implications for assessment of tumor response. Clin Cancer Res. 2023;29(1):143\u201353. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3143.","journal-title":"Clin Cancer Res"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07738-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07738-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07738-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:26:05Z","timestamp":1777274765000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07738-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7738"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07738-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The precursor of FAPI-46 and reference standard [natGa]Ga-FAPI-46 (ABX, Radeberg, Germany) were made freely available.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Review Committee of the Amsterdam UMC (Institutional review board number 2022.0640) and was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Witten informed consent was obtained from all individual participants included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}